Ubs Oncology Impact Fund L.P. Harpoon Therapeutics, Inc. (HARP) insider trading activity

Ubs Oncology Impact Fund L.P. is > 10% Shareholder of Harpoon Therapeutics, Inc.. Currently has a direct ownership of 3.65 Million shares of HARP, which is worth approximately $0. The most recent transaction as insider was on Feb 12, 2019, when has been sold 447 shares (Common Stock) at a price of $14.0 per share, resulting in proceeds of $6,258. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.65M

0% 3M change

0% 12M change

Total Value Held $0

UBS Oncology Impact Fund L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 12 2019	SELL Open market or private sale	$6,258 $14.0 p/Share	447 Reduced 0.01%	3,648,422 Common Stock
Feb 12 2019	BUY Exercise of in-the-money or at-the-money derivatives securities	$6,355 $0.05 p/Share	127,096 Added 3.37%	3,648,869 Common Stock
Feb 12 2019	BUY Open market or private purchase	$3,500,000 $14.0 p/Share	250,000 Added 6.03%	3,898,422 Common Stock
Feb 12 2019	BUY Conversion of derivative security	-	3,521,773 Added 50.0%	3,521,773 Common Stock

Also insider at

CGEM

Cullinan Oncology, Inc. Healthcare

> 10% Shareholder

TCRR

TCR2 THERAPEUTICS INC. Healthcare

> 10% Shareholder

ONCR

Oncorus, Inc. Healthcare

> 10% Shareholder

UOI